On March 17, 2026, the NMPA released 26 medical device industry standards, including the revised YY/T 1406—2026: Guidance on the Application of GB/T 42062 to Medical Device Software, effective March 1, 2027. It replaces YY/T 1406.1—2016 and clarifies how the risk management principles of GB/T 42062—2022 should be implemented within the software lifecycle defined by YY/T 0664—2020.
This standard forms an integral part of China’s Digital Health regulatory framework and serves as a supplement to other software & AI related documents, such as those on medical device software, cybersecurity, AI-assisted software, and human factors engineering.
Please click HERE for our technical review on AI-aided Software Guideline. The article was published on BioWorld, a Hong Kong-based biotech magazine.
Click HERE for our webinar on “SaMD Registration Requirements: China & US Perspectives”
Click HERE for our webinar on “Key Takeaways and Best Practices of China Human Factor/Usability”
From “Document Compliance” to “Risk Management”
The document marks a structural shift in regulatory expectations. China is moving from a process-driven approach—focused on whether software development steps are documented—to a model that emphasizes whether risk is systematically identified, controlled, and monitored across the entire lifecycle.
Under this new framework, risk management is no longer a standalone deliverable. It must be embedded into every stage of software development and operation:
- Requirements must reflect risk control objectives, not just functional intent
- Architecture must demonstrate how high-risk functions are isolated or mitigated
- Testing must verify the effectiveness of risk controls, not just functionality
- Changes must trigger risk re-evaluation, not just regression testing
This shift raises the bar for traceability and internal consistency. It also aligns China more closely with global regulatory thinking, while placing stronger emphasis on real-world risk control effectiveness.
Converging Safety, Security, and System-Level Responsibility
Another defining feature of YY/T 1406—2026 is the integration of traditionally separate domains. Functional safety and cybersecurity are no longer treated as parallel concerns. Instead, they are increasingly evaluated within a unified risk framework.
In practice, this means that issues such as:
- Software defects or abnormal inputs
- Interface mismatches or data transmission errors
- Unauthorized access or configuration flaws
- Network disruptions or failed updates
may all be considered pathways to medical risk if they can impact clinical outcomes.
At the same time, the boundary of responsibility is expanding. Devices now interact with hospital systems, cloud platforms, and mobile applications, forming complex ecosystems. The new standard implicitly requires a system-level perspective—where risks arising from interoperability, deployment environments, and user access are part of the manufacturer’s consideration.
For companies, this represents a shift from managing “a product” to managing “a system in context.”
What This Means for SaMD—and Why Overseas Manufacturers Are Well Positioned
The impact of this regulatory evolution is particularly significant for Software as a Medical Device (SaMD), including AI-driven applications, diagnostic software, and remote monitoring platforms. Regulators will increasingly focus on whether companies can demonstrate a complete and credible evidence chain:
- How risks are identified and translated into software requirements
- How control measures are implemented and validated
- How post-market data feeds back into risk evaluation and updates
For AI-based products, additional challenges—such as data bias, model drift, and performance variability—must also be addressed within this structured risk framework.
For overseas manufacturers, however, this shift presents a clear opportunity. Many already operate under mature quality systems and have experience with stringent regulatory authorities. Their strengths—robust design controls, validated processes, and established compliance practices—translate well into China’s evolving expectations.
Entering the Chinese market is therefore not about starting from scratch, but about alignment and localization. With the right strategy, existing global documentation and systems can be adapted to meet NMPA requirements efficiently.
China Med Device, LLC supports this process end-to-end, helping overseas companies bridge regulatory gaps and accelerate market entry. Its services include:
- Regulatory pathway planning and gap assessment
- Localization of technical documentation and risk management files
- Coordination of testing, clinical evaluation, and registration submission
- Ongoing support for post-market compliance and lifecycle management
As YY/T 1406—2026 approaches implementation, early preparation will be critical. The most time-intensive work lies not in producing documents, but in ensuring that systems, processes, and evidence are fully aligned. Email info@ChinaMedDevice.com for more information